MarketTwits
266K subscribers
78.6K photos
2.96K videos
1.1K files
83.2K links
Вся информация на канале не является рекомендацией

связь - @MarketTwits_info
связь - [email protected]
VK - https://vk.com/id635239814

в подборках не участвуем, партнерки не практикуем, свой канал не рекламируем, менеджеры по рекламе не нужны
Download Telegram
🇺🇸#акции #сша #premarket
премаркет США - акции - заметные движения:

ВВЕРХ


#RH +26% RH - after the company reported better-than-expected earnings for its first quarter and raised FY2019 guidance.

#RNET +12% RigNet, Inc.

#FRO +10% Frontline Ltd. -following reports that a tanker had been struck by a torpedo off the coast of UAE.

#TIGO +10% Millicom International Cellular S.A. - after Kinnevik withdrew public offering of shares in Millicom due to unfavorable market condition.

#PRVB +10% Provention Bio, Inc. - after the company cancelled its secondary offering.

#OXM +9% Oxford Industries Inc - after the company reported better-than-expected earnings for its first quarter on Wednesday.

#NETS +9% Netshoes (Cayman) Limited - after Brazilian company Magazine Luiza SA lifted its offer to buy Netshoes to $3.7 per share.

#RVLV +7% Revolve Group, Inc.

#TLRD +6% Tailored Brands Inc - following upbeat Q1 results.

#DRD +6% DRDGOLD Limited

#HP +6% Helmerich & Payne, Inc.

#LULU +5% Lululemon Athletica Inc. - after the company reported stronger-than-expected results for its first quarter and raised FY2019 earnings guidance.

#HOFT +5% Hooker Furniture Corporation- after falling 24% on Wednesday.

#GLW +5% Corning Incorporated

#CRWD +5% CrowdStrike Holdings, Inc. -after climbing 70% on Wednesday.

#TSN +4% Tyson Foods, Inc. -after the company introduced its first plant-based and blended products line, Raised & Rooted.

ВНИЗ

#SVRA -73% Savara Inc. - Savara said a Phase 3 study dubbed IMPALA that evaluated its Molgradex for the treatment of autoimmune alveolar pulmonary proteinosis, or aPAP, did not meet its primary endpoint. An average A-aDO2 improvement of 12.1 mmHg was observed in the continuous dosing compared to an 8.8 mmHg improvement in the placebo arm, with an estimated 4.6 mmHg treatment difference suggesting the primary endpoint was not met.

#HEB -18% Hemispherx Biopharma, Inc. - after the company announced the first patient has been treated in the Phase 2 recurrent ovarian cancer program evaluating Ampligen in combination with Pembrolizumab and Cisplatin.

#MCRB -16% Seres Therapeutics Inc - after reporting a $60 million common stock offering.

#WKHS -10% Workhorse Group Inc. -after dropping 6% on Wednesday.

#IMRN -9% Immuron Limited - after climbing 14% on Wednesday.

#NEPT -9% Neptune Wellness Solutions Inc. -after reporting fourth-quarter sales of $5.79 million, up from $5.394 million year-over-year.

#JAGX -8% Jaguar Health, Inc. - after declining 23% on Wednesday.

#ICAD -8% iCAD, Inc. - iCAD priced its 1.636 million shares at $5.50 per share.

#CONE -7% CyrusOne Inc.

#BKE -6% The Buckle, Inc.

#LAUR -5% Laureate Education, Inc. -after reporting an offering of 10 million shares of common stock.

#ITCI -5% Intra-Cellular Therapies, Inc. - after rising 11% on Wednesday.

#HEXO -4% HEXO Corp. - after reporting Q3 results.

#TMDX -4% TransMedics Group, Inc.